Skip to main content
. Author manuscript; available in PMC: 2022 Oct 3.
Published in final edited form as: Pediatr Blood Cancer. 2021 Jul 31;68(10):e29265. doi: 10.1002/pbc.29265

FIGURE 2.

FIGURE 2

Sub-clonal evolution of tumor in patient 1 through the course of diagnosis and treatment.

Serial whole genome sequencing (83–107X) of the pre-treatment and post-treatment primary adrenal tumor as well as metastases from CNS, liver, and bilateral lungs indicated that there was branching evolution leading to subclones with distinct driver mutations confined to different tumor sites. The BRAF V600E mutation was found in the post-treatment adrenal tumor only, while CNS tumors and lung/liver tumors had two different ALK mutations, F1174L and F1245I, respectively.